Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 12, 2013, under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 370,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,502 pence per share; lowest price paid was 1,488.5 pence per share.
- Treasury Holdings (Settled): 495,321,327 shares (9.17% of total issued share capital).
- Treasury Holdings (Including Unsettled): 496,431,327 shares (10.12% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,699,282 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 370,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.12% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (4,907,699,282) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (10.12% including unsettled shares).
- Review the remaining authorization for share repurchases under the May 2012 shareholder mandate.